[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-2-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-2-infection":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100636255","a-study-to-evaluate-performance-usability-and-contrived-result-interpretation-of-truplex-hivhepbsyphilis-rapid-test-100636255",false,"NCT07563309","A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test","A Study to Evaluate the Performance, Usability, and Contrived Result Interpretation of TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test by Trained Personnel at Near-Patient and Point-of-Care Settings","Inclusion Criteria:\n\n* 18 years of age or older\n* Subject is able to provide and willing to sign and date the Informed Consent Form\n* Subject is able to complete the required testing on the allocated testing day.\n* Subject able to speak\u002Fread\u002Fwrite English or a translator is available\n* Subject is getting tested for HIV, and\u002For Syphilis, and\u002For Hepatitis B for one or more of the following reasons:\n\n  * At risk for any one of the target diseases\n  * Having signs or symptoms indicative of the target diseases\n  * Routine testing\n  * Note: Subjects who are pregnant and re-infected are eligible to participate\n* Unknown HIV or known HIV positive status with less than 12 months of Anti-Retroviral Treatment (ART).\n* Subject is willing to provide the fingerstick blood sample(s) and whole blood samples collected through venous blood draw (approximately 16 ml) required for the study.\n* Subject willing to participate in the study site's standard of care counselling and testing program and receive the study site's standard of care test results\n\nExclusion Criteria:\n\n* Subject has a bleeding disorder\n* Subject is currently undergoing Syphilis treatment\n* Subject has received any experimental HIV vaccine\n* Subject received HBV vaccine within the last 7 days\n* Known HIV positive subjects and currently on ART for 12 months or longer\n* Any condition which, in the opinion of the Investigator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of study assessment, consent form and questionnaire etc. or bias the study outcome.",true,"ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objectives of this study are as follows:\n\nTo evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care settings\n\nTo evaluate the usability of the TruPlex test through:\n\nStructured usability assessments, via a questionnaire, completed by trained operators in point-of-care settings.\n\nTo assess user interpretation accuracy through a contrived result interpretation questionnaire, where intended users evaluate a set of pre-defined test results (e.g., strong\u002Fweak positives, negatives, invalids).\n\nTo monitor test system reliability, including invalid rates.",[27,28,29,30],"HIV 1 Infection","HIV 2 Infection","Syphilis Infection","Hepatitis B Infection",[32],"TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test","RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-04","ACTUAL",{"date":39,"type":37},"2025-12-18",{"date":41,"type":21},"2027-01-01",{"name":43,"class":44},"bioLytical Laboratories","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100636763","a-study-to-evaluate-the-performance-and-usability-of-truplex-hivhepbsyphilis-rapid-test-100636763","NCT07569913","A Study to Evaluate the Performance, and Usability of TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test","A Study to Evaluate the Performance, and Usability of TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test by Trained Personnel at Near-Patient and Point-of-Care Settings","Inclusion Criteria:\n\n* 18 years of age or older\n* Subject is able to provide and willing to sign and date the Informed Consent Form\n* Subject is able to complete the required testing on the allocated testing day.\n* Subject is able to speak\u002Fread\u002Fwrite English or a translator is available\n* Subject is getting tested for HIV, and\u002For Syphilis, and\u002For Hepatitis B for one or more of the following reasons:\n\n  * At risk for any one of the target diseases\n  * Having signs or symptoms indicative of the target diseases\n  * Routine testing\n  * Note: Subjects who are pregnant and re-infected are eligible to participate\n* Unknown HIV or known HIV positive status with less than 12 months of Anti-Retroviral Treatment (ART).\n* Subject is willing to provide the fingerstick blood sample(s) and whole blood samples collected through venous blood draw (approximately 16 ml) required for the study.\n* Subject willing to participate in the study site's standard of care counselling and testing program and receive the study site's standard of care test results\n\nExclusion Criteria:\n\n* Subject has a bleeding disorder\n* Subject is currently undergoing Syphilis treatment\n* Subject has received any experimental HIV vaccine\n* Subject received HBV vaccine within the last 7 days\n* Known HIV positive subjects and currently on ART for 12 months or longer\n* Any condition which, in the opinion of the Investigator, would make the participant unsuitable or unsafe for enrolment or could interfere with the completion of study assessment, consent form and questionnaire etc. or bias the study outcome.",{"count":53,"type":21},500,[24],"To evaluate the clinical performance of each analyte (HIV, HBsAg, and Syphilis) on the TruPlex HIV\u002FHepB\u002FSyphilis Rapid Test (TruPlex Test) using capillary blood (fingerstick), EDTA whole blood, EDTA-plasma, and SST-serum samples collected by trained operators at point-of-care settings. Additionally, to evaluate the usability of the TruPlex test through: structured usability assessments, via a questionnaire, completed by trained operators in point-of-care settings.",[57,28,29,30],"HIV1 Infection",[32],"NOT_YET_RECRUITING",{"date":61,"type":37},"2026-05-06",{"date":63,"type":21},"2026-09-01",{"date":65,"type":21},"2027-06-01",{"name":43,"class":44},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":67},"100455833","ex-vivo-characterization-and-targeting-of-the-latent-hiv-infected-reservoir-to-cure-hiv-100455833","NCT05215704","Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV","EX VIVO","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Confirmed HIV-1 or HIV-2 infection.\n\nExclusion Criteria:\n\n1. Inability to place 2.5 cm venous catheter or perform phlebotomy\n2. Major comorbidities:\n\n   A. Severe symptomatic anemia B. Recent symptomatic cardiovascular event (unstable angina pectoris, decompensated heart failure, myocardial infarction).\n3. The inability to participate due to any other relevant medical, social, environmental, psychological, factors or according to the HIV treating physician's judgement",{"count":76,"type":21},40,"OBSERVATIONAL","Combination antiretroviral therapy (cART) blocks intracellular human immunodeficiency virus (HIV) replication in CD4+ T-lymphocytes, but fails to eliminate latent HIV infected CD4+ T-lymphocytes. About 7 (range \\\u003C1-100) in 106 of these cells are latently infected and can cause reactivation of proviral HIV when cART is stopped. These latently infected cells form the reservoir and must be targeted in order to cure HIV. We would like to further investigate this reservoir and assess potential interventions to eradicate it. One promising option is to further study the influence of HIV latency disruptors (latency reversing agents, LRA) on the HIV infected reservoir. These agents are used in shock and kill strategies that disrupt latency by LRA followed by the selective (induced) killing of the reservoir cell due to viro-pathogenic effects.\n\nFor accurate assessment of the reservoir and potential cure strategies, including the impact of LRA on the reservoir, a large reservoir and sufficient cells for analysis are desirable. Our understanding on the reservoir comes from in vitro lymphocyte models and early ex vivo studies. Additional studies of patients with different clinical phenotypes including untreated versus treated versus the rare individuals that control HIV spontaneously are increasingly relevant to the field. Especially this last category represent biological examples of viral control without cART and are useful to study the factors that set them apart from those that need treatment for their HIV. This study aims to deepen our understanding of the HIV reservoir and cure strategies, foremost, shock and kill strategies. We will do this by setting up a durable ex vivo platform for HIV reservoir and cure studies of which the samples can be used for hypothesis generation for in-vivo studies.\n\nA project from the Erasmus MC HIV Eradication Group (EHEG).",[80,81,82],"HIV Infections","HIV-1-infection","HIV-2 Infection",[84,85,86],"HIV","HIV cure","HIV reservoir","2024-02-12",{"date":89,"type":37},"2024-02-14",{"date":91,"type":37},"2012-01-01",{"date":93,"type":21},"2030-12-31",{"name":95,"class":96},"Erasmus Medical Center","OTHER"]